Adding a Bispecific to R-CHOP Halves Lymphoma Progression Risk
Adding a Bispecific to R-CHOP Halves Lymphoma Progression Risk
Adding the bispecific antibody epcoritamab to standard R-CHOP chemotherapy reduced the risk of disease progression or death by 51% in a Phase 3 trial involving patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). The positive topline results, announced by Genmab and AbbVie on October 5, 2026, could support a new first-line treatment option for people with this aggressive form of blood cancer.
The findings came from the EPCORE DLBCL-2 trial, which compared epcoritamab plus R-CHOP with R-CHOP alone in patients with newly diagnosed DLBCL and an International Prognostic Index (IPI) score of 2–5. The companies said they plan to engage global regulatory authorities based on the results. The findings remain topline data, and the combination is investigational in this setting.
Phase 3 Trial Shows Significant Improvement in Progression-Free Survival
EPCORE DLBCL-2 evaluated whether adding epcoritamab to established chemoimmunotherapy could improve outcomes for patients receiving initial treatment for DLBCL.
The study met its primary endpoint, demonstrating a statistically significant improvement in progression-free survival (PFS). Patients receiving epcoritamab plus R-CHOP had a 51% lower relative risk of disease progression or death than those receiving R-CHOP alone.
The reported hazard ratio was 0.49, with a 95% confidence interval of 0.36–0.67 and a p-value below 0.0001. These results indicate a substantial difference between the treatment groups in the risk of experiencing a PFS event during the study period.
However, a relative reduction in risk does not mean that 51% more patients were cured or that every patient benefited. Full study results, including absolute PFS rates, follow-up duration and additional clinical outcomes, will be important for assessing the magnitude and durability of the benefit.
What Is Diffuse Large B-Cell Lymphoma?
Diffuse large B-cell lymphoma is an aggressive type of non-Hodgkin lymphoma that develops from B lymphocytes, a type of white blood cell involved in immune defence.
The disease can progress rapidly and may affect lymph nodes or organs outside the lymphatic system. Although many patients respond to initial treatment, some experience relapse or do not achieve lasting disease control.
The International Prognostic Index helps clinicians assess prognosis using factors such as age, disease stage, performance status, involvement of multiple extranodal sites and blood levels of lactate dehydrogenase. EPCORE DLBCL-2 focused on patients with IPI scores of 2–5, a group with clinically significant risk requiring effective treatment.
How Epcoritamab Works With R-CHOP
Epcoritamab is a bispecific antibody designed to bind both CD20, a protein found on B cells, and CD3, a protein on T cells. By engaging both targets, the medicine brings T cells into proximity with B cells and helps direct immune-cell activity against malignant cells.
This mechanism differs from conventional chemotherapy, which attacks rapidly dividing cells through other biological processes. Combining the two approaches aims to use both chemotherapy and the body's immune system to control lymphoma.
R-CHOP consists of five medicines:
Rituximab: A monoclonal antibody targeting CD20 on B cells.
Cyclophosphamide: A chemotherapy agent that damages cancer-cell DNA.
Doxorubicin: A chemotherapy drug that interferes with DNA function.
Vincristine: A medicine that disrupts the cellular structures required for cell division.
Prednisone: A corticosteroid with lympholytic and anti-inflammatory effects.
Epcoritamab is administered subcutaneously. In EPCORE DLBCL-2, it was evaluated with a fixed treatment duration alongside R-CHOP, rather than as a replacement for the chemotherapy regimen.
Safety and Treatment Considerations
Genmab and AbbVie reported that the safety profile of epcoritamab combined with R-CHOP was generally well tolerated and consistent with the previously reported safety profiles of the individual treatments.
Nevertheless, bispecific antibodies can cause important immune-related adverse effects. These include cytokine release syndrome (CRS), an inflammatory reaction that can range from mild symptoms to a serious medical emergency. Neurological toxicity is another recognised concern with some T-cell-engaging therapies. Chemotherapy also carries risks, including infection, low blood-cell counts, nausea and other treatment-related complications.
The complete EPCORE DLBCL-2 safety dataset will be needed to understand the frequency and severity of adverse events, treatment discontinuations and any additional monitoring requirements.
For clinicians, the decision to use a new combination will depend on the full evidence, patient characteristics, existing treatment options and the eventual regulatory label.
How the Findings Could Affect First-Line Lymphoma Treatment
The results add to efforts to improve first-line treatment for DLBCL, where researchers are exploring ways to increase remission rates and reduce the risk of relapse.
A bispecific antibody combination could offer a new approach if the PFS benefit is confirmed through detailed data and regulatory review. The potential clinical value will depend not only on delaying progression but also on the durability of responses, overall survival, treatment tolerability and patients' quality of life.
The findings should also be considered alongside other evolving first-line treatment strategies. Different regimens may be appropriate for different patient groups, and cross-trial comparisons cannot reliably establish which treatment is superior without direct comparative evidence.
Epcoritamab is already used in certain settings for relapsed or refractory B-cell lymphoma, but its use with R-CHOP for newly diagnosed DLBCL remains investigational. The EPCORE DLBCL-2 findings do not, by themselves, establish a new approved standard of care.
Genmab and AbbVie Prepare for Regulatory Discussions
Genmab and AbbVie said they intend to discuss the EPCORE DLBCL-2 findings with global regulatory authorities. The results are an important development milestone for the companies' collaboration in oncology.
The next steps will include presentation of more detailed clinical data and regulatory evaluation of the combination in newly diagnosed DLBCL. Those data will help clarify the treatment's absolute benefit, longer-term outcomes and safety profile.
For the wider oncology sector, the trial adds evidence that T-cell-engaging bispecific antibodies may have a role earlier in the treatment course of certain blood cancers. Whether epcoritamab plus R-CHOP becomes a routine first-line option will depend on the full clinical dataset and subsequent regulatory decisions.
Sources:
General-Purpose Polystyrene (GPPS)
Found this useful?
